DigiFab® in Patients with Severe PreeclampsiaStatus: open
17-019 - [1005180-2] A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of DigiFab® in Antepartum Subjects with Severe Preeclampsia
Treatment for Preeclampsia
This study evaluates the use of Digoxin immune fab in addition to expectant management in the treatment of severe preeclampsia as compared to placebo. IRB Number 17-019
SponsorsThis trial is sponsored by Velo Bio, LLC.
Interested in Clinical Trial?
Providers Associated With This Trial
- Bassam H. Rimawi, M.D.Maternal-Fetal PhysicianAssistant Professor of Obstetrics and Gynecology